BAX as the mediator of C-MYC sensitizes acute lymphoblastic leukemia to TLR9 agonists

BACKGROUND: The prognosis of B-cell acute lymphoblastic leukemia (B-ALL) has improved significantly with current first-line therapy, although the recurrence of B-ALL is still a problem. Toll-like receptor 9 (TLR9) agonists have shown good safety and efficiency as immune adjuvants. Apart from their i...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Ling, Zhou, Lei, Han, Wei, Chen, Jingtao, Gu, Xiaoyi, Hu, Zheng, Yang, Yongguang, Li, Wei, Zhang, Xiaoying, Niu, Chao, Chen, Yongchong, Li, Hui, Cui, Jiuwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9921080/
https://www.ncbi.nlm.nih.gov/pubmed/36765389
http://dx.doi.org/10.1186/s12967-023-03969-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9921080/
https://www.ncbi.nlm.nih.gov/pubmed/36765389
http://dx.doi.org/10.1186/s12967-023-03969-z

Ejemplares similares